MYUNGMOON Pharm co.,Ltd (KRX:017180)
South Korea · Delayed Price · Currency is KRW 1,777.00
+46.00 (2.66%)
Feb 3, 2026, 3:30 PM KST
MYUNGMOON Pharm co.,Ltd Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 193,642 | 186,443 | 169,567 | 152,135 | 137,760 | 127,853 |
Other Revenue | - | - | -0 | -0 | -0 | - |
| 193,642 | 186,443 | 169,567 | 152,135 | 137,760 | 127,853 | |
Revenue Growth (YoY) | 7.49% | 9.95% | 11.46% | 10.44% | 7.75% | -14.39% |
Cost of Revenue | 88,030 | 81,949 | 74,658 | 74,528 | 75,965 | 82,658 |
Gross Profit | 105,612 | 104,494 | 94,909 | 77,607 | 61,795 | 45,195 |
Selling, General & Admin | 98,290 | 100,698 | 90,417 | 66,846 | 66,213 | 68,191 |
Research & Development | 3,094 | 2,059 | 2,970 | 1,711 | 2,065 | 535.06 |
Amortization of Goodwill & Intangibles | - | 9.81 | 58.6 | 70.52 | 68.3 | 96.82 |
Other Operating Expenses | 1,499 | 1,344 | 1,358 | 1,365 | 1,506 | 4,908 |
Operating Expenses | 97,751 | 102,565 | 93,946 | 71,173 | 67,675 | 74,159 |
Operating Income | 7,861 | 1,929 | 963.77 | 6,434 | -5,881 | -28,964 |
Interest Expense | -5,110 | -5,352 | -5,137 | -3,735 | -3,042 | -4,142 |
Interest & Investment Income | 49.81 | 109.68 | 225.05 | 152.17 | 199.05 | 215.75 |
Currency Exchange Gain (Loss) | 33.2 | 45.93 | 46 | -0.77 | 17.34 | 0.39 |
Other Non Operating Income (Expenses) | 960.21 | 826.22 | -132.13 | -275.32 | 1,163 | 3,768 |
EBT Excluding Unusual Items | 3,795 | -2,441 | -4,035 | 2,575 | -7,543 | -29,122 |
Gain (Loss) on Sale of Investments | 26.72 | 63.24 | -36.24 | 95.02 | 498.6 | 1,892 |
Gain (Loss) on Sale of Assets | -489.85 | -512.21 | 25.61 | -14.03 | 895.37 | -30.58 |
Asset Writedown | -854.35 | -854.35 | -736.22 | -4.2 | -448.76 | - |
Other Unusual Items | - | - | - | - | - | -34.27 |
Pretax Income | 2,477 | -3,744 | -4,782 | 2,652 | -6,598 | -27,295 |
Income Tax Expense | 1,686 | 45.4 | 92.61 | -5,324 | 206.14 | 458.5 |
Earnings From Continuing Operations | 791.51 | -3,790 | -4,874 | 7,976 | -6,804 | -27,753 |
Minority Interest in Earnings | 668.72 | 755.39 | 349.41 | -108.07 | -60.25 | 114.43 |
Net Income | 1,460 | -3,035 | -4,525 | 7,868 | -6,865 | -27,639 |
Net Income to Common | 1,460 | -3,035 | -4,525 | 7,868 | -6,865 | -27,639 |
Shares Outstanding (Basic) | 33 | 33 | 34 | 34 | 34 | 29 |
Shares Outstanding (Diluted) | 33 | 33 | 34 | 34 | 34 | 29 |
Shares Change (YoY) | 0.14% | -0.58% | -0.38% | - | 15.48% | 20.01% |
EPS (Basic) | 43.60 | -90.62 | -134.35 | 232.74 | -203.06 | -944.14 |
EPS (Diluted) | 43.22 | -91.00 | -134.35 | 232.74 | -203.06 | -944.14 |
Free Cash Flow | -2,447 | -2,109 | -8,164 | 3,744 | 480.28 | -18,681 |
Free Cash Flow Per Share | -73.06 | -62.99 | -242.39 | 110.75 | 14.21 | -638.16 |
Gross Margin | 54.54% | 56.05% | 55.97% | 51.01% | 44.86% | 35.35% |
Operating Margin | 4.06% | 1.03% | 0.57% | 4.23% | -4.27% | -22.65% |
Profit Margin | 0.75% | -1.63% | -2.67% | 5.17% | -4.98% | -21.62% |
Free Cash Flow Margin | -1.26% | -1.13% | -4.81% | 2.46% | 0.35% | -14.61% |
EBITDA | 11,919 | 5,994 | 5,132 | 10,672 | -1,678 | -24,763 |
EBITDA Margin | 6.16% | 3.21% | 3.03% | 7.02% | -1.22% | -19.37% |
D&A For EBITDA | 4,057 | 4,066 | 4,168 | 4,238 | 4,203 | 4,201 |
EBIT | 7,861 | 1,929 | 963.77 | 6,434 | -5,881 | -28,964 |
EBIT Margin | 4.06% | 1.03% | 0.57% | 4.23% | -4.27% | -22.65% |
Effective Tax Rate | 68.05% | - | - | - | - | - |
Advertising Expenses | - | 1,348 | 1,372 | 1,314 | 993.55 | 5,906 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.